ESMO Voices from China | Professor Hongxia Wang: B7-H3-Targeted ADC SYS6043 Shows Encouraging Antitumor Activity and Manageable Safety in Advanced Breast Cancer

ESMO Voices from China | Professor Hongxia Wang: B7-H3-Targeted ADC SYS6043 Shows Encouraging Antitumor Activity and Manageable Safety in Advanced Breast Cancer

In recent years, antibody-drug conjugates (ADCs) have become a major force reshaping the treatment landscape of advanced breast cancer. However, significant challenges remain in the management of patients with resistance to multiple lines of therapy and those with difficult-to-treat disease, highlighting the urgent need for breakthroughs involving novel therapeutic targets. At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Hongxia Wang of Fudan University Shanghai Cancer Center presented safety and efficacy data for SYS6043, a B7-H3-targeted ADC, in patients with advanced breast cancer in a Rapid Oral presentation (Abstract No. 5RO). Following the presentation, Oncology Frontier interviewed Professor Hongxia Wang of Fudan University Shanghai Cancer Center at ESMO to discuss the rationale for selecting B7-H3 as a therapeutic target in advanced breast cancer, potential explanations for differences in efficacy across molecular subtypes, and the future positioning and development of B7-H3-targeted ADCs.
ESMO Voices from China | Professor Jian Zhang: BFv Offers New Hope for Later-Line TNBC Treatment After Resistance to TOP1 Inhibitor-Based ADCs

ESMO Voices from China | Professor Jian Zhang: BFv Offers New Hope for Later-Line TNBC Treatment After Resistance to TOP1 Inhibitor-Based ADCs

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. At the congress, Professor Jian Zhang of Fudan University Shanghai Cancer Center led a study of the Nectin-4-targeted antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, BFv), with Professor Yanchun Meng presenting the Phase II results in patients with locally advanced or metastatic triple-negative breast cancer (TNBC) in an oral presentation. Against this background, Oncology Frontier invited Professor Jian Zhang to discuss the rationale for BFv's "target switching plus payload switching" strategy, the study's efficacy and safety findings, and its potential role in future treatment sequencing.
2026 Breast Cancer Quality Control Conference | Professor Qiao Li: Fertility Preservation and Rational Drug Use

2026 Breast Cancer Quality Control Conference | Professor Qiao Li: Fertility Preservation and Rational Drug Use

In breast cancer diagnosis and treatment, standardized care and quality control remain long-term priorities for ensuring consistent standards of care across China and benefiting more patients. As treatment options evolve rapidly and clinical concepts continue to advance, clinicians are increasingly focused not only on improving patient survival but also on quality of life and individual patient needs. Recently, the 2026 Conference on Standardized Breast Cancer Diagnosis, Treatment, and Quality Control was held in Beijing. Oncology Frontier invited Professor Qiao Li from the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, who co-chaired the conference, for an interview. Drawing on frontline clinical practice, she shared her perspectives on fertility preservation for young patients with breast cancer, updates to the Guidelines for Rational Drug Use in Breast Cancer, and other topics of major interest in the field.
2026 Breast Cancer Quality Control Conference | Professor Fei Ma: Reviewing Progress and Shaping the Future of Breast Cancer Quality Control

2026 Breast Cancer Quality Control Conference | Professor Fei Ma: Reviewing Progress and Shaping the Future of Breast Cancer Quality Control

Breast cancer is one of the most commonly diagnosed malignancies among women in China. Standardized diagnosis and treatment, together with quality control, are essential for improving patient survival and strengthening the national cancer prevention and control system. Recently, the 2026 Conference on Standardized Breast Cancer Diagnosis, Treatment, and Quality Control was held in Beijing. The meeting took place at a pivotal stage in China's efforts to promote standardized cancer diagnosis and treatment through a breast cancer pilot program, drawing widespread attention from the medical community. Oncology Frontier invited Professor Fei Ma from the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Chair of the Conference, for an in-depth interview. He shared his perspectives on the conference's academic agenda, key aspects of comprehensive breast cancer management, and the annual quality control report.
ESMO LBA Insights | Professor Jong Chul Park Discusses the HexAgon-HN Study

ESMO LBA Insights | Professor Jong Chul Park Discusses the HexAgon-HN Study

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain. During the head and neck cancer oral presentation session, the Phase II results of the HexAgon-HN study (LBA42) were presented. The study evaluated the efficacy and safety of the hexavalent OX40 agonist INBRX-106 combined with pembrolizumab (P) versus pembrolizumab monotherapy as first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) and a PD-L1 combined positive score (CPS) ≥20.
ESMO Voices from China | Professor Man Li: Final OS Results from OptiTROP-Breast01 Demonstrate Durable Survival Benefit with Sacituzumab Tirumotecan in Previously Treated mTNBC

ESMO Voices from China | Professor Man Li: Final OS Results from OptiTROP-Breast01 Demonstrate Durable Survival Benefit with Sacituzumab Tirumotecan in Previously Treated mTNBC

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. Professor Man Li of the Second Hospital of Dalian Medical University presented the final overall survival (OS) analysis of the Phase III OptiTROP-Breast01 study of sacituzumab tirumotecan (Sac-TMT) in a Rapid Oral presentation (Abstract No. 4639RO). The results were also published in the internationally renowned oncology journal Annals of Oncology. Against this background, Oncology Frontier invited Professor Man Li to discuss the latest findings, the characteristics of the survival benefit with extended follow-up, and the implications for the treatment landscape of previously treated locally recurrent or metastatic triple-negative breast cancer (mTNBC).
ESMO Voices from China | Professor Lei Fan: SWITCH Study Reveals Payload Cross-Resistance After ADC Failure and Points to New Sequencing Strategies

ESMO Voices from China | Professor Lei Fan: SWITCH Study Reveals Payload Cross-Resistance After ADC Failure and Points to New Sequencing Strategies

At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Lei Fan of Fudan University Shanghai Cancer Center presented results from the SWITCH platform study. This prospective, open-label, Phase II platform study was designed to investigate the efficacy and safety of sequential treatment with novel ADCs targeting different antigens in patients with HER2-negative metastatic breast cancer whose disease had progressed following prior antibody-drug conjugate (ADC) therapy. Following the presentation, Oncology Frontier invited Professor Lei Fan to discuss the rationale and design of the SWITCH study, its key findings, and the implications for future ADC sequencing strategies and drug development.
Dr. Jie Xiong: From Fatal to Curable—Mechanistic Breakthroughs and New Treatment Advances in Extranodal NK/T-Cell Lymphoma

Dr. Jie Xiong: From Fatal to Curable—Mechanistic Breakthroughs and New Treatment Advances in Extranodal NK/T-Cell Lymphoma

Extranodal natural killer/T-cell lymphoma (NKTCL) is an aggressive lymphoma characterized by a strong association with Epstein–Barr virus (EBV) and substantial biological heterogeneity. As our understanding of the mechanisms underlying disease development and progression continues to deepen, and therapeutic strategies such as asparaginase and immune checkpoint inhibitors are increasingly explored, the treatment landscape of NKTCL is undergoing profound changes. Identifying new therapeutic targets based on disease pathogenesis and translating basic research findings into clinical practice have become important priorities for further improving patient outcomes.
10th West China Urologic Oncology Tianfu Academic Conference | Professor Liangyou Gu: ADCs Are Reshaping Urothelial Cancer Treatment, with Earlier-Line Use and Comprehensive Management Key

10th West China Urologic Oncology Tianfu Academic Conference | Professor Liangyou Gu: ADCs Are Reshaping Urothelial Cancer Treatment, with Earlier-Line Use and Comprehensive Management Key

The 10th West China Urologic Oncology Tianfu Academic Conference was held in Chengdu from November 5 to 7, 2026. As antibody-drug conjugates (ADCs) enter different stages of urothelial carcinoma treatment, drug selection, treatment timing, and sequencing strategies have become new clinical challenges. On this occasion, Oncology Frontier – UroStream invited Professor Liangyou Gu of the Chinese PLA General Hospital to share insights into the key recommendations of the Expert Guidance on the Clinical Application of ADCs in Advanced Urothelial Carcinoma, focusing on first-line treatment selection, later-line sequencing, and safety management.
ESMO 2026 | Professor Liangyou Gu: CAIX-Targeted PET/CT Opens a New Chapter in Precision Staging of Clear Cell Renal Cell Carcinoma

ESMO 2026 | Professor Liangyou Gu: CAIX-Targeted PET/CT Opens a New Chapter in Precision Staging of Clear Cell Renal Cell Carcinoma

At ESMO 2026, Professor Liangyou Gu from the Chinese PLA General Hospital reported a prospective study evaluating the diagnostic and staging performance of [68Ga]Ga-DPI-4452 PET/CT targeting carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma (ccRCC). Historically, ccRCC staging has relied heavily on CT/MRI, while the use of FDG PET/CT has been limited by its lack of specificity. How to achieve more precise characterization and staging has therefore remained a major clinical challenge. Against this backdrop, Oncology Frontier – UroStream invited Professor Liangyou Gu to provide an in-depth interpretation of the rationale for selecting this imaging target and the potential future applications of this novel imaging technique.